Summary
- Shares have risen by around 25% since my initial article.
- I provide a recap of the bullish thesis and recent news.
- Future catalysts this year include additional data from the phase 2 study of MGTA-456 in inherited metabolic disorders and phase 1 data for MGTA-145.
- Longer term, my interest lies with C100 and C200 programs, which would enable stem cell transplant without the need for toxic chemotherapy and radiation regimen (gamechanger).
- The stock remains a Buy for investors with long-term, multi-year time frame. For the purposes of ROTY, I plan to revisit closer to the end of the year.
- Looking for a community to discuss ideas with? ROTY features a chat room of like-minded investors sharing investing ideas and strategies. Get started today »
Shares of Magenta Therapeutics (NASDAQ:MGTA) have risen by around 25%, since my August 20th article suggested this IPO should be on readers' radar. To be fair, at one point, the stock lost almost two-thirds of its value before rebounding this year.
While I revisited this one earlier in ROTY, it's not currently one of our "active ideas", considering we focus on near-term runners. That said, I've gotten a number of inquiries on Magenta as more readers are intrigued by their unique mission of improving the bone marrow transplant process and making the procedure available to a higher number of patients. Let's take a closer look at how the story has evolved.
